Ido Laish M.D., Maor Maman M.D., Nir Marcus M.D., Eran Rotman M.D., Jehoshua Dor M.D., Ariel Hourvitz M.D.
{"title":"Biochemical terrorism: the medical threat in the twenty-first century","authors":"Ido Laish M.D., Maor Maman M.D., Nir Marcus M.D., Eran Rotman M.D., Jehoshua Dor M.D., Ariel Hourvitz M.D.","doi":"10.1016/j.sram.2004.04.012","DOIUrl":"10.1016/j.sram.2004.04.012","url":null,"abstract":"<div><p><em>September 11, 2001, forever changed the landscape surrounding terrorism. The oceans no longer protected the United States from terrorists. And as incidences in the Philippines, Spain, Iraq, and other corners of the globe have found, no place on the planet can be considered risk-free. Unfortunately, not only must the world be concerned with acts of violence and destruction, but also with the threat of a more insidious nature—chemical and biological terrorism. According to a March 29, 2004, article in the</em> New York Times<em>, the Pentagon released parts of an unclassified document suggesting that the United States is “woefully ill-prepared to detect and respond to a bioterrorist assault.” In this article, our authors offer us a first-hand window into an important and regrettably necessary area of medicine that could affect us both as physicians and citizens in the twenty-first century.</em> <span><figure><span><img><ol><li><span>Download : <span>Download full-size image</span></span></li></ol></span><span><span><p><span>Fig 1</span>. </p></span></span></figure></span></p><p>—<strong>The Editors</strong></p><p>Biochemical terrorism—the deliberate dispersion of viruses, bacteria, fungi, and organic or inorganic toxin agents, to kill, mutilate, and create chaos—is a real threat that all countries must cope with today. Both sovereign nations and terror organizations now have the capability to produce and use biochemical agents, and some of them have already demonstrated their eagerness to do so. The development of instant communication has been a further inducement to the terrorists. Each event is reported almost immediately in the media, bringing recognition and reputation to the executors (1–3).</p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 2","pages":"Pages 108-113"},"PeriodicalIF":0.0,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.04.012","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"37832357","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"OA","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Targeting hirsutism: a new approach","authors":"Boaz Kurtis M.D. , Sarah Brenner M.D.","doi":"10.1016/j.sram.2004.04.010","DOIUrl":"10.1016/j.sram.2004.04.010","url":null,"abstract":"<div><p><span>Hirsutism, the appearance of facial hair on women in a male pattern distribution, is a problem with potential medical, social, and psychological implications for millions of women. Hirsutism can reflect the presence of an underlying </span>systemic disease<span>, namely one that results in hyperandrogenic states, or it may seem to be idiopathic. Many methods of treatment have been used over the years, from pharmacological and surgical treatment for underlying disease to mechanical means of hair removal. We discuss hirsutism and review the clinical experience with a topical cream approved for facial hair removal, called eflornithine (Vaniqa), which acts by inhibiting new growth by an enzyme inhibition mechanism. Therapeutic trials and our clinical experience have shown promising results with this agent in diminishing unwanted facial hair in women.</span></p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 2","pages":"Pages 101-107"},"PeriodicalIF":0.0,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.04.010","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"121535301","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"An industry perspective on the evolution of hormonal contraceptive development","authors":"Preeti Chadha PharmD , Andrew J. Friedman MD","doi":"10.1016/j.sram.2004.04.011","DOIUrl":"10.1016/j.sram.2004.04.011","url":null,"abstract":"<div><p>This article examines key drivers for the evolution of hormonal contraceptive<span> research, including changes in governmental (e.g., Food and Drug Administration [FDA], National Institutes of Health [NIH]) regulatory policies and pharmaceutical drug development. The modernization of regulatory guidances served as the catalyst for hormonal contraceptive research and set the foundation for the study of additional aspects related to women's health and the inclusion of women in clinical trials in both the public and private sectors. The trends in hormonal contraceptive development over the past fifty years provide an interesting case study of the changes in women's health care (WHC) research from an industry perspective. In both WHC research in general and hormonal contraceptive development in particular, an effort to improve the overall health of women has remained an overarching theme.</span></p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 2","pages":"Pages 119-124"},"PeriodicalIF":0.0,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.04.011","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"131836205","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Spirituality, wellness, and quality of life","authors":"Harold G. Koenig M.D.","doi":"10.1016/j.sram.2004.04.004","DOIUrl":"10.1016/j.sram.2004.04.004","url":null,"abstract":"<div><p>Spirituality generally relates to better mental health, greater well-being, and higher quality of life. Physical health and medical outcomes may also be affected. Besides its connection with health, there are several practical reasons why health professionals ought to inquire about spirituality, particularly in patients with serious or chronic illness. Spiritual beliefs influence medical decisions that affect health care, may conflict with medical care, and can influence the doctor–patient relationship either positively or negatively. Support from the faith community can help patients cope better with difficult health stressors, may improve early detection of disease, and can enhance compliance with medical treatment. Although important for all patients, spiritual issues are particularly important for women, the elderly, the chronically ill, the disabled, and members of certain ethnic groups.</p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 2","pages":"Pages 76-82"},"PeriodicalIF":0.0,"publicationDate":"2004-06-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.04.004","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"116811309","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"The gender gap: new challenges in women's health","authors":"Gloria E Sarto M.D., Ph.D.","doi":"10.1016/j.sram.2004.02.003","DOIUrl":"https://doi.org/10.1016/j.sram.2004.02.003","url":null,"abstract":"<div><p>Until recently the focus of women's health research and policy has been on reproductive health, but new public health issues have emerged that must be addressed. Among them are a need to examine the basic biology of sex differences in health and disease; the elimination of disparities in health status and health outcomes among diverse populations of women; and a mandate to care for a growing population of aging women.</p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 1","pages":"Pages 9-14"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.02.003","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"136833832","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Serono: innovative research in reproductive health and infertility","authors":"Paul Lammers M.D.","doi":"10.1016/j.sram.2004.02.009","DOIUrl":"https://doi.org/10.1016/j.sram.2004.02.009","url":null,"abstract":"<div><p><span>The number of couples delaying childbirth is increasing and one out of five American women is having a first child after the age of 35. As a consequence, infertility is becoming more commonplace and the challenges in </span>reproductive health and infertility are growing. The need for innovative research is as compelling as ever. The keys to research in the field over the next several years are furthering our understanding of the biology of reproduction and targeting unmet medical needs.</p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 1","pages":"Pages 53-54"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.02.009","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137056119","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Mining the human genome for new health therapies","authors":"Moshe Zilberstein M.D.","doi":"10.1016/j.sram.2004.02.002","DOIUrl":"https://doi.org/10.1016/j.sram.2004.02.002","url":null,"abstract":"<div><p>The completion of the Human Genome Project heralds advances in determining the foundations of disease and in developing new therapeutic treatments. Tests already exist for the detection of some genetic abnormalities that can cause disease, and more are being developed. In the future, pharmacogenetics will be used to tailor treatment to specific patients.</p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 1","pages":"Pages 4-8"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.02.002","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137056116","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
{"title":"Men at risk: occupation and male infertility","authors":"Paul Claman M.D., F.R.S.C.(C)","doi":"10.1016/j.sram.2004.02.005","DOIUrl":"https://doi.org/10.1016/j.sram.2004.02.005","url":null,"abstract":"<div><p>There is accumulating evidence that workplace exposure to toxic substances contributes to male infertility<span>. Men suffering from infertility problems may do well to look at their occupations, where exposure to certain substances may be a contributory factor, if not a direct cause, of infertility.</span></p><p>Most of the studies to date are either case reports or epidemiological studies (population-based, case-control, or cohort studies). Additional, controlled studies need to be done to ascertain the effects of occupational toxins on male infertility. Until then, men and their employers should work together to minimize exposure to these substances.</p></div>","PeriodicalId":89480,"journal":{"name":"Sexuality, reproduction & menopause","volume":"2 1","pages":"Pages 19-26"},"PeriodicalIF":0.0,"publicationDate":"2004-03-01","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"https://sci-hub-pdf.com/10.1016/j.sram.2004.02.005","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"137056118","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":0,"RegionCategory":"","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}
求助内容：
应助结果提醒方式：
京公网安备 11010802042870号
